As on Wednesday, ProQR Therapeutics N.V (NASDAQ: PRQR) got off with the flyer as it spiked 6.40% to $2.16, before settling in for the price of $2.03 at the close. Taking a more long-term approach, PRQR posted a 52-week range of $1.07-$4.62.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was 25.70%. Meanwhile, its Annual Earning per share during the time was 25.70%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -12.40%. This publicly-traded company’s shares outstanding now amounts to $105.34 million, simultaneously with a float of $72.22 million. The organization now has a market capitalization sitting at $227.26 million. At the time of writing, stock’s 50-day Moving Average stood at $1.67, while the 200-day Moving Average is $2.28.
ProQR Therapeutics N.V (PRQR) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Biotechnology industry. ProQR Therapeutics N.V’s current insider ownership accounts for 31.36%, in contrast to 40.17% institutional ownership.
ProQR Therapeutics N.V (PRQR) Earnings and Revenue Records
ProQR Therapeutics N.V’s EPS decrease for this current 12-month fiscal period is -12.40% and is forecasted to reach -0.54 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will decrease by -12.79% through the next 5 years, which can be compared against the 25.70% growth it accomplished over the previous five years trading on the market.
ProQR Therapeutics N.V (NASDAQ: PRQR) Trading Performance Indicators
Let’s observe the current performance indicators for ProQR Therapeutics N.V (PRQR). It’s Quick Ratio in the last reported quarter now stands at 4.10. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 11.16.
In the same vein, PRQR’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.35, a figure that is expected to reach -0.09 in the next quarter, and analysts are predicting that it will be -0.54 at the market close of one year from today.
Technical Analysis of ProQR Therapeutics N.V (PRQR)
Through scrutinizing the latest numbers posted by the [ProQR Therapeutics N.V, PRQR], it can be observed that its last 5-days Average volume of 0.46 million was lower the volume of 0.47 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 86.23% While, its Average True Range was 0.11.
Raw Stochastic average of ProQR Therapeutics N.V (PRQR) in the period of the previous 100 days is set at 68.13%, which indicates a major fall in contrast to 91.11% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 55.24% that was lower than 77.39% volatility it exhibited in the past 100-days period.
